GLS-6150

Phase 1Biologic

GGeneOne Life Science, Inc.

GLS-6150 is one of 49 biologic programs targeting Hepatitis C Virus Infection. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis C Virus InfectionActive, not recruiting

Hepatitis C Virus InfectionPhase 1

Active, not recruiting

Competition

Competitive Landscape

76 competitors in Hepatitis C Virus Infection

#DrugCompanyPhaseTrials

Actos

Crestor

Avelox

Lexapro

Sovaldi

6 6

Victrelis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—7

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Promacta

Olysio

3 10

Ombitasvir/paritaprevir/ritonavir

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatitis C Virus Infection1 trial

Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection

Completed·GGeneOne Life Science, Inc.·Phase 1·NCT03674125·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GLS-6150. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLS-6150 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLS-6150. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GeneOne Life Science, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: GGeneOne Life Science, Inc.

GLS-6150

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatitis C Virus Infection1 trial

References

Drug Info

Quick Facts

Related News